These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 9368480

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
    Karlman M, Holmström M, Wiman B.
    Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
    [Abstract] [Full Text] [Related]

  • 6. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex.
    Amano K, Arai M, Koshihara K, Suzuki T, Kagawa K, Nishida Y, Fukutake K.
    Am J Hematol; 1995 Aug; 49(4):310-7. PubMed ID: 7639276
    [Abstract] [Full Text] [Related]

  • 7. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
    Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H.
    Thromb Haemost; 1993 Mar 01; 69(3):240-6. PubMed ID: 7682339
    [Abstract] [Full Text] [Related]

  • 8. Further evidence for recessive inheritance of von Willebrand disease with abnormal binding of von Willebrand factor to factor VIII.
    López-Fernández MF, Blanco-López MJ, Castiñeira MP, Batlle J.
    Am J Hematol; 1992 May 01; 40(1):20-7. PubMed ID: 1566742
    [Abstract] [Full Text] [Related]

  • 9. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.
    Casonato A, Pontara E, Zerbinati P, Zucchetto A, Girolami A.
    Am J Clin Pathol; 1998 Mar 01; 109(3):347-52. PubMed ID: 9495210
    [Abstract] [Full Text] [Related]

  • 10. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF. Characterization of abnormal vWF/FVIII interaction.
    Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M.
    Blood; 1990 Jan 01; 75(1):20-6. PubMed ID: 2104761
    [Abstract] [Full Text] [Related]

  • 11. Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis.
    Veyradier A, Caron C, Ternisien C, Wolf M, Trossaert M, Fressinaud E, Goudemand J.
    Haemophilia; 2011 Nov 01; 17(6):944-51. PubMed ID: 21371195
    [Abstract] [Full Text] [Related]

  • 12. Patients with severe von Willebrand disease are insensitive to the releasing effect of DDAVP: evidence that the DDAVP-induced increase in plasma factor VIII is not secondary to the increase in plasma von Willebrand factor.
    Cattaneo M, Simoni L, Gringeri A, Mannucci PM.
    Br J Haematol; 1994 Feb 01; 86(2):333-7. PubMed ID: 8199023
    [Abstract] [Full Text] [Related]

  • 13. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
    Peerlinck K, Jacquemin MG, Arnout J, Hoylaerts MF, Gilles JG, Lavend'homme R, Johnson KM, Freson K, Scandella D, Saint-Remy JM, Vermylen J.
    Blood; 1999 Apr 01; 93(7):2267-73. PubMed ID: 10090936
    [Abstract] [Full Text] [Related]

  • 14. Interaction between VWF and FVIII in treating VWD.
    Miesbach W, Berntorp E.
    Eur J Haematol; 2015 Nov 01; 95(5):449-54. PubMed ID: 25605439
    [Abstract] [Full Text] [Related]

  • 15. Laboratory Testing for von Willebrand Factor: Factor VIII Binding for the Diagnosis or Exclusion of Type 2N von Willebrand Disease: An Update.
    Favaloro EJ, Mohammed S, Vong R, Pasalic L.
    Methods Mol Biol; 2023 Nov 01; 2663():679-691. PubMed ID: 37204745
    [Abstract] [Full Text] [Related]

  • 16. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ, Gadisseur A, Vangenegten I, Schroyens W, Berneman Z.
    Acta Haematol; 2009 Nov 01; 121(2-3):119-27. PubMed ID: 19506358
    [Abstract] [Full Text] [Related]

  • 17. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease.
    Atiq F, Meijer K, Eikenboom J, Fijnvandraat K, Mauser-Bunschoten EP, van Galen KPM, Nijziel MR, Ypma PF, de Meris J, Laros-van Gorkom BAP, van der Bom JG, de Maat MP, Cnossen MH, Leebeek FWG, WiN study group.
    Br J Haematol; 2018 Jul 01; 182(1):93-105. PubMed ID: 29767844
    [Abstract] [Full Text] [Related]

  • 18. Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.
    Lippi G, Franchini M, Salvagno GL, Montagnana M, Poli G, Guidi GC.
    J Thromb Thrombolysis; 2008 Oct 01; 26(2):150-3. PubMed ID: 17786534
    [Abstract] [Full Text] [Related]

  • 19. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
    Federici AB.
    Blood Coagul Fibrinolysis; 2005 Apr 01; 16 Suppl 1():S17-21. PubMed ID: 15849522
    [Abstract] [Full Text] [Related]

  • 20. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
    Saenko EL, Shima M, Rajalakshmi KJ, Scandella D.
    J Biol Chem; 1994 Apr 15; 269(15):11601-5. PubMed ID: 7512568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.